Kyntra Bio Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $4.6M-84.4% YoYTTM through 30 Jun 2026
Net Income $183.2MTTM through 30 Jun 2026
Free Cash Flow -$38.1MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | -1,090.0% |
| Net Margin | 3,968.6% |
Returns
181.2%ROA
Balance Sheet Health
Debt / Equity-2.49x
Current Ratio2.69x
Net Debt$24.4M
Cash & Equivalents$50.6M
Quality Metrics
Altman Z-Score-24.39
Piotroski F-Score2 / 9
FCF Margin-824.6%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $6.4M
Diluted EPS$45.30TTMFY2025: $45.38
Dividend
No dividend
Capital Allocation
Capex Intensity0.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Therapeutics Development and Commercialization | $3.7M | +37.0% | View detailsFinalizing Phase 3 trial protocol for roxadustat in lower-risk MDS following FDA feedback; Phase 2 monotherapy trial of FG-3246 in mCRPC on track for interim analysis in 4Q 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.